- Report
- May 2023
- 91 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Book
- September 2019
- 302 Pages
- Report
- April 2025
- 275 Pages
China
From €3641EUR$4,000USD£3,092GBP
- Report
- March 2025
- 214 Pages
China
From €3641EUR$4,000USD£3,092GBP
- Report
- March 2025
- 65 Pages
China
From €1638EUR$1,800USD£1,392GBP
- Report
- September 2024
- 121 Pages
China
From €1638EUR$1,800USD£1,392GBP
- Report
- March 2024
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Report
- November 2021
- 284 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Report
- November 2021
- 747 Pages
Global
From €3641EUR$4,000USD£3,092GBP
- Report
- July 2024
- 245 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- July 2024
- 280 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Book
- August 2023
- 224 Pages
- Book
- June 2023
- 384 Pages
The Anticancer Agent market is a segment of the Healthcare Services industry that focuses on the development and distribution of drugs and treatments for cancer. These agents are designed to target and destroy cancer cells while minimizing the damage to healthy cells. They can be administered orally, intravenously, or topically, depending on the type of cancer and the patient's individual needs. Anticancer agents are used in combination with other treatments such as radiation and chemotherapy to provide the best possible outcome for the patient.
The Anticancer Agent market is highly competitive, with many companies vying for market share. Companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
